

# MANCHESTER UNIVERSITY NHS FOUNDATION TRUST

## BOARD OF DIRECTORS

<b>Report of:</b>	Director of Strategy
<b>Paper prepared by:</b>	Director of Strategy
<b>Date of paper:</b>	12 March 2018
<b>Subject:</b>	Strategic Development Update
<b>Purpose of Report:</b>	<p>Indicate which by ✓</p> <ul style="list-style-type: none"> <li>• Information to note ✓</li> <li>• Support</li> <li>• Resolution</li> <li>• Approval</li> </ul>
<b>Consideration of Risk against Key Priorities:</b>	All individual strategic developments are risk assessed and monitored through the Board Assurance and Risk Management processes.
<b>Recommendations:</b>	<p>The Board of Directors is asked to note progress and the current position in relation to the following key strategic areas:</p> <ul style="list-style-type: none"> <li>- NHS England national service reviews, including the status of reviews currently underway and MFT's involvement in these</li> <li>- GM Health &amp; Social Care Partnership including the Theme 3 Transformation Programme and projects under GM Cancer</li> <li>- MHCC's refresh of the Locality plan and key priorities for the year, plus how MFT has committed to support these</li> </ul>
<b>Contact:</b>	<p><u>Name:</u> Darren Banks, Director of Strategy</p> <p><u>Tel:</u> 0161 276 5676</p>

## Introduction

The purpose of this paper is to update the Board of Directors in relation to the strategic issues that we are currently progressing.

### 1. National strategic developments

#### NHS England national service reviews

National clinical reviews have been established in 24 areas to review a range of services commissioned directly by NHS England. Six of these reviews have now completed and the remaining 18 are at various stages of development ranging from the development of a case for change, to public consultation and engagement, to implementation or procurement. These 18 services account for around £3.8bn, or 20-25% of specialised commissioning expenditure.

The table below shows each of the areas being reviewed and the stage of development.

Service area	Current phase	Service area	Current phase
1 Proton Beam (interim)	Procurement/Implementation	10 Haemoglobinopathy	Case for change
2 PET-CT phase 2	Procurement/Implementation	11 Infectious Diseases	Case for change
3 Childrens & YP Cancer	Case for change	12 Paediatric (PICU & surgery) review	Case for change
4 Cancer Surgery	Case for change	13 Genomic labs	Procurement/Implementation
5 Low & Med secure	Procurement/Implementation	14 Gender identity	Case for Change
6 Hyperbaric Oxygen Therapy	Public consultation and engagement	15 Congenital Heart Disease	Public Consultation/Implementation
7 Spinal cord injury	Procurement/Implementation	16 Auditory Brain Implants	Procurement/Implementation
8 Intestinal Failure	Public consultation and engagement	17 Transforming Care Partnerships (LD)	Procurement/Implementation
9 Prosthetics	Case for change	18 Paediatric Obesity surgery	Procurement/Implementation

The following sets out the MFT involvement to date:

- ACHD (implementing)
- The Trust is working up a delivery plan for the development of a Level 2 plus service
- Genomic lab redesignation (implementing)
- Agreement has been reached in relation to future genomics provision across North West and we are on track to complete tender documents by 19th March deadline
- Paediatric critical care (case for change)
- The emerging view is that increase in PHDU capacity is required and a 'Managed Network' model proposed.

Work is underway to progress the areas above and to understand the potential implications of those at the earlier stages of development for MFT.

## 2. Greater Manchester

### Theme 3 transformation

The table below shows the current status of the Theme 3 projects. New projects now being taken forward within the programme include cardiac and respiratory services.

	Implementation				Transformation						
Lead	MFT			SRFT	MFT			SFT	WWL	MFT & Bolton	MFT
	Healthier Together	Urology cancer	Gynae* cancer	OG cancer	Vascular	Breast cancer	Paeds	Benign urology	Ortho MSK	Cardiac	Resp
<b>Case for change</b>	√	√	√	√	√	√	√	√	√		
<b>Co-dependencies and clinical standards</b>	√	√	√	√	√	√			√		
<b>ECAP submission</b>	√	√	√	√	√	√			√		
<b>Models of care</b>	√	√	√	√							
<b>Options appraisal</b>	√	√	√	√							
<b>Implementation</b>	√	√	√	√							

### GM Cancer

#### *GM Haematological Cancer Diagnostic Partnership (HCDP)*

The inaugural meeting of the HCDP Partnership Board took place on 15<sup>th</sup> February, chaired by MFT haematologist and clinical director John Burthem. Service leads at MFT as lead provider, are working closely with colleagues at the Christie (key provider) to establish the service and begin to repatriate samples to the GM services that were being sent outside of GM for analysis, from July. Key priorities in establishing the service over the next two to three months include implementing a new IT system to support integrated reporting on samples received across GM and developing an activity and financial model in order to develop the costs of service and prices that will be charged to users.

## 3. Manchester

### Manchester Health and Care Commissioning (MHCC)

MHCC is in the process of updating their Manchester locality plan to both reflect the achievements over the last year, predominantly the formation of the Single Hospital Service, MHCC's integrated commissioning organisation and the LCO, and confirm priorities for the year ahead. MHCC's seven key priorities for 2018/19 have now been developed and focus on:

1. Developing high quality, effective residential, nursing and home care
2. Delivering effective out of hospital care (respiratory, cardiovascular and diabetes)
3. Developing core primary care services
4. Tackling health inequalities
5. Delivering strategic programmes for children's transformation, mental health, learning disability, cancer and system resilience.
6. Delivering a transformed health and care system (acute reconfiguration, LCO procurement and MHCC phase 2)
7. Delivering national and statutory requirements and transform health and care in Manchester

MFT has been supporting the process and is committing to ensure that the ongoing implementation of the SHS supports these priorities and the locality plan more broadly by:

- Supporting the development of the LCO
- Progressing the standardisation of acute care and support services as part of Themes 3 and 4 Transformation programmes
- Making ongoing improvements in productivity and efficiency
- Investing in research and innovation
- It's role as a local employer through enhancing staff education and training opportunities.

#### **4. Actions / Recommendations**

The Board of Directors is asked to note progress and the current position in relation to the following key strategic areas:

- NHS England national service reviews, including the status of reviews currently underway and MFT's involvement
- GM Health & Social Care Partnership including the Theme 3 Transformation Programme and projects under GM Cancer
- MHCC's refresh of the Locality plan and key priorities for the year, and how MFT has committed to support these.